TriSalus Life Sciences (TLSI) Long-Term Investments (2020 - 2023)

TriSalus Life Sciences has reported Long-Term Investments for 4 years, with the latest figure at $12.1 million in Q2 2023.

• For the quarter ending Q2 2023, Long-Term Investments fell 95.18% year-over-year to $12.1 million; the trailing twelve-month figure through Jun 2023 stood at $12.1 million (down 95.18% YoY), and the FY2022 full-year result was $19.8 million, down 92.07% from the prior year.
• Long-Term Investments for Q2 2023 stood at $12.1 million, down from $20.2 million in the prior quarter.
• The five-year high for Long-Term Investments was $251.0 million in Q3 2022, with the low at $12.1 million in Q2 2023.
• Historically, Long-Term Investments has averaged $186.7 million across 4 years, with a median of $250.0 million in 2021.
• Annual changes were most pronounced in 2022 — Long-Term Investments grew 0.38% — and 2023, when it slumped 95.18%.
• TriSalus Life Sciences' Long-Term Investments stood at $250.0 million in 2020, then gained by 0.0% to $250.0 million in 2021, then tumbled by 92.07% to $19.8 million in 2022, then slumped by 39.09% to $12.1 million in 2023.
• The last three Long-Term Investments figures came in at $12.1 million (Q2 2023), $20.2 million (Q1 2023), and $19.8 million (Q4 2022), per Business Quant data.